Key result
Adding the MTHFR C677T variant improves early-onset CAD risk discrimination beyond conventional models.
Why the study?
Does the MTHFR C677T variant (rs1801133) increase the risk of early onset coronary artery disease and alter cardiometabolic profiles in the Chinese Han population?
Case-Control (n=228)
Does the MTHFR C677T variant (rs1801133) increase the risk of early onset coronary artery disease and alter cardiometabolic profiles in the Chinese Han population?
Effect estimate: IDI 0.022
p-value: p=0.012
The MTHFR C677T variant (TT genotype) is an independent risk factor for early onset coronary artery disease in the Chinese Han population, associated with worse cardiometabolic profiles and providing incremental value for risk stratification.
Background: The MTHFR C677T polymorphism (rs1801133) is a well-documented genetic variant in cardiovascular research, yet its mechanistic role in early onset coronary artery disease (EOCAD) remains poorly characterized in East Asian populations. This study aimed to explore whether rs1801133 modulates EOCAD risk by altering proatherogenic cardiometabolic traits in the Chinese Han population. Methods: This rigorous case–control study enrolled 128 patients with angiographically confirmed EOCAD and 100 age- and sex-matched controls with nonobstructive coronary arteries. Standard enzymatic assays were used to detect blood lipid profiles and one-carbon metabolic markers. We constructed prediction models integrating conventional cardiometabolic risk factors with rs1801133. Model incremental performance was evaluated via integrated discrimination improvement (IDI) and net reclassification improvement (NRI), with 1000 bootstrap replicates for internal validation. Results: The rs1801133 T allele was significantly associated with higher EOCAD susceptibility. Compared with CC carriers, TT genotype individuals exhibited adverse cardiometabolic profiles, including elevated low-density lipoprotein cholesterol (LDL-C) (3.22 ± 0.48 vs. 2.83 ± 0.85 mmol/L, p < 0.05), systolic blood pressure (145.25 ± 25.28 vs. 133.03 ± 19.89 mmHg, p = 0.01), diastolic blood pressure (90.31 ± 15.56 vs. 85.68 ± 13.19 mmHg, p = 0.04), and homocysteine (16.98 ± 9.48 vs. 12.67 ± 4.47 μmol/L, p < 0.05). Receiver operating characteristic (ROC) analysis identified LDL-C as the dominant EOCAD predictor, and logistic regression confirmed rs1801133 as an independent risk factor. Adding rs1801133 to the base model significantly improved IDI (0.022, p = 0.012) and NRI (0.291, p = 0.040). Bootstrap validation with minimal model optimism (0.034–0.036) verified favorable internal stability. Conclusions: rs1801133 is a functional genetic determinant of EOCAD in the Chinese Han population. The TT genotype defines a high-risk subgroup aggravated by combined dyslipidemia and hyperhomocysteinemia. rs1801133 yielded significant incremental discrimination and reclassification value over traditional risk factors. These findings support personalized EOCAD risk stratification, highlighting intensive LDL-C management for T allele carriers as a promising early intervention strategy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a case-control in Early onset coronary artery disease (EOCAD) (n=228). MTHFR C677T Variant (rs1801133) vs. CC genotype was evaluated on EOCAD risk prediction improvement (Integrated Discrimination Improvement) (IDI 0.022, p=0.012). The MTHFR C677T variant (rs1801133) was associated with higher EOCAD susceptibility, and its addition to base models significantly improved risk discrimination (IDI 0.022, p=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: